Xilio Therapeutics Doses First Patient in Phase 1/2 Trial of XTX501 for Metastatic Lung Cancer

Bitget2026/10/26 11:30

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold. Trade now!

A welcome pack worth 6200 USDT for new users! Sign up now!

Xilio Therapeutics dosed the first patient in a Phase 1/2 trial of XTX501 for metastatic non-small cell lung cancer.
The trial enrolls patients previously treated with anti-PD(L)-1 therapy.
XTX501 combines PD-1 inhibition with masked IL-2, aiming to deliver tumor-selective immune activation while limiting toxicity.
Initial Phase 1 data are expected in the fourth quarter of 2027.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Xilio Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202610260730PRIMZONEFULLFEED9852442) on October 26, 2026, and is solely responsible for the information contained therein.

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.

Trade now！

Xilio Therapeutics Doses First Patient in Phase 1/2 Trial of XTX501 for Metastatic Lung Cancer

You may also like

Crypto prices